Preparation of cell-permeable Cre recombinase by expressed protein ligation by Soo Lyu & Hyockman Kwon
Lyu and Kwon BMC Biotechnology  (2015) 15:7 
DOI 10.1186/s12896-015-0126-zRESEARCH ARTICLE Open AccessPreparation of cell-permeable Cre recombinase
by expressed protein ligation
Soo Kyung Lyu and Hyockman Kwon*Abstract
Background: Protein transduction is safer than viral vector-mediated transduction for the delivery of a therapeutic
protein into a cell. Fusion proteins with an arginine-rich cell-penetrating peptide have been produced in E. coli, but
the low solubility of the fusion protein expressed in E. coli impedes the large-scale production of fusion proteins
from E. coli.
Results: Expressed protein ligation is a semisynthetic method to ligate a bacterially expressed protein with a chemically
synthesized peptide. In this study, we developed expressed protein ligation-based techniques to conjugate synthetic
polyarginine peptides to Cre recombinase. The conjugation efficiency of this technique was higher than 80%.
Using this method, we prepared semisynthetic Cre with poly-L-arginine (ssCre-R9), poly-D-arginine (ssCre-dR9)
and biotin (ssCre-dR9-biotin). We found that ssCre-R9 was delivered to the cell to a comparable level or more
efficiently compared with Cre-R11 and TAT-Cre expressed as recombinant fusion proteins in E. coli. We also found
that the poly-D-arginine cell-penetrating peptide was more effective than the poly-L-arginine cell-penetrating
peptide for the delivery of Cre into cell. We visualized the cell transduced with ssCre-dR9-biotin using avidin-FITC.
Conclusions: Collectively, the results demonstrate that expressed protein ligation is an excellent technique for
the production of cell-permeable Cre recombinase with polyarginine cell-penetrating peptides. In addition, this
approach will extend the use of cell-permeable proteins to more sophisticated applications, such as cell imaging.
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Protein delivery is regarded as a safer and useful alternative
to gene delivery for the induction of genome editing and
alterations in the gene expression profile of cells. Gene de-
livery through the transfection of plasmid DNAs or viral
transductions inevitably imposes potential complications
to gene alteration and is subject to safety problems. In
contrast, there is a slight possibility that a genome
would be altered by proteins delivered directly into cells.
Furthermore, proteins become degraded and are eventu-
ally removed from cells. This property makes protein de-
livery more suitable for cell therapy applications in which
a transient, rather than a sustained, action of transcription
factors is required.
Due to the impermeability of proteins through a non-
polar cell membrane, protein delivery typically requires a* Correspondence: hmkwon@hufs.ac.kr
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unless otherwise stated.protein delivery vector. Cell-penetrating peptides (CPPs)
have emerged as the most promising protein delivery
vector and are distinct from liposomes and other encap-
sulation technologies. CPPs are defined as short peptides
(10–30 amino acids) that facilitate the cellular uptake of
large macromolecules with a low membrane permeability
[1]. Since the discovery that Tat48–60 enables the HIV-1
Tat protein to penetrate cells and activates HIV-1-specific
target genes [2-4], several CPPs, including penetratin and
transportan, have been reported. CPPs are either arginine-
rich, amphipathic, or hydrophobic [5]. Recently, a cell-
type-specific CPP, Xentry, is found from the X-protein of
the hepatitis B virus [6]. The arginine-rich CPPs are short
basic peptides highly enriched with arginine and lysine
residues. The guanidinium groups of arginines play a
central role in the cell penetrating activity of the arginine-
rich CPPs, and in fact, homooligomers of arginine (7–12
arginines) are significantly more effective than native
arginine-rich CPPs, such as Tat48–60 [7,8].al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of CPPs suggest that their translocation mechanisms are
not identical. Most importantly, the arginine-rich CPPs are
less toxic than the amphipathic CPPs, and the arginine-
rich CPPs do not cause membrane leakage at low micro-
molar concentrations where the arginine-rich CPPs are
highly effective for cellular uptake [9-11]. Considering their
low toxicity and high efficiency, the arginine-rich CPPs
have been preferentially selected as protein delivery vec-
tors. For example, the polyarginine fusion proteins of Oct4,
Sox2, Klf4, and c-Myc have been delivered into somatic
cells to reprogram them into iPSCs [12,13], and TAT-Pdx1,
TAT-Ngn3, and TAT-MafA have been used to stimulate
pancreatic β-cell differentiation [14-16]. Moreover, R7-
CARM1 has been delivered to human mesenchymal stem
cells to modulate their differentiation potential [17].
The arginine-rich CPP proteins have been produced in
E. coli as recombinant fusion proteins. However, the fusion
of the arginine-rich CPPs to proteins markedly decreases
the solubility of the proteins, and when these are over-
expressed in E. coli, they generally form the inclusion bod-
ies. To obtain the soluble and active form of the proteins,
the inclusion bodies have to be solubilized by denaturation
agents, such as urea, and then the proteins have to beScheme 1
Figure 1 General scheme for expressed protein ligation. In scheme 1,
the thiol group of an N-terminal cysteine of the peptides. In scheme 2, the
acyl Shift proceed in one-pot.refolded [12,14,16,18]. Alternatively, the temperature used
to induce protein expression has to be lowered to main-
tain the solubility of the arginine-rich CPP proteins when
expressed in E. coli [15,17]. However, either method se-
verely decreases the efficiency of the recovery of the active
proteins, which impedes the large-scale production of the
arginine-rich CPP proteins from E. coli.
Expressed protein ligation (EPL) is a semisynthetic tech-
nique that conjugates a synthetic peptide containing an
N-terminal cysteine to a C-terminal thioester through a
native chemical ligation reaction (Figure 1). A C-terminal
thioester of a protein is generated by the thiolysis of a re-
combinant intein fusion protein expressed in E. coli. The
orthogonal reactivity, the production of a native peptide
bond, and the high yield in an aqueous buffer at neutral
pH and low temperature make EPL a powerful ligation
method that introduces a synthetic peptide into recom-
binant proteins. EPL has been used to incorporate unnat-
ural amino acids, fluorophores, and post-translational
modifications to proteins [19]. In this study, we employed
EPL to conjugate a synthetic polyarginine CPP polypeptide
to a recombinant protein expressed in a soluble form in
E. coli. The major advantage of this EPL-based technique
over the preparation of recombinant polyarginine CPPScheme 2 
the Cre-thioester is isolated from the intein-His for further reaction with
thiolysis by MESNA, the transthioesterification reaction, and the S-N
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nique is not subject to the solubility problem as long as
protein can be produced as soluble form in E. coli. In
addition, the EPL-based technique allows the preparation
of cell-permeable proteins with novel arginine-rich CPPs
composed of unnatural amino acids, guanidinium-rich
peptoids, or biotin.
The applicability of the EPL-based technique for the
preparation of arginine-rich CPP proteins was previously
tested using the enhanced green fluorescent protein (EGFP)
as a model protein [20]. The flow cytometry study showed
that EGFP conjugated with arginine 12-mer (R12) prepared
by the EPL-based technique was delivered to cells with
an efficiency comparable to that obtained with EGFP-R12
expressed as a fusion protein in E. coli. However, the
EGFP-R12 molecules taken up by cells appeared to ac-
cumulate at the cell surface or be entrapped in endosomes,
and it was uncertain whether these were delivered to the
cytoplasm. The bio-activity of EGFP-12R in the cells was
not examined in the study.
The Cre recombinase from bacteriophage P1 is a DNA
sequence-specific recombinase that catalyzes the recom-
bination of DNA between two loxP sites. Cre has been
widely used to generate a tissue-specific or inducible knock-
out in transgenic mice or conditional gene expression in
cells. Cre carries the nuclear localization sequence (NLS)-
like elements that direct the efficient entry of Cre protein
into the nucleus of mammalian cells [21]. In addition,
cells harboring a loxP-STOP-loxP reporter gene, such
as β-galactosidase or EGFP, allow us to monitor Cre-
mediated recombination by Cre protein [22,23]. In thisFigure 2 Semi-synthesis of Cre-R9 by EPL. (A) Expression of Cre-intein-H
purified by Ni-NTA chromatography (lane 4). After dialysis, Cre-intein-His w
24 h (lane 5). Cre-R9 was isolated from intein-His and CGSGG-R9 peptide b
size marker. The 12% SDS-PAGE gel was stained with Coomassie Brilliant Bl
time, and it separated Cre-R9 from Cre-thioester as the distinct bands (lane
(lane 2). Lane 1, size marker. The gel was stained with Coomassie Brilliant B
the integrated peak areas of densitometry analysis of lane 3, was 84:16.study, we prepared a cell-permeable Cre protein through
the conjugation of synthetic polyarginine CPPs to recom-
binant Cre expressed in E. coli using EPL. The semisyn-
thetic Cre-R9 (ssCre-R9) prepared by EPL had the similar
enzymatic activity as Cre. We found that ssCre-R9 effi-
ciently led to recombination events in living cells. It was
previously reported that d-isomer polyarginine CPPs are
more efficient than l-isomer polyarginine CPPs for the
delivery of fluorescently labeled peptides [7]. Biotin
(vitamin H or B-7) is a water-soluble vitamin, and the
strong biotin-avidin interaction allows imaging of the
cells that uptake a biotin-containing protein. Because
EPL allows the incorporation of d-isomer amino acids
and peptide mimetics into a protein, we prepared Cre
proteins with the d-isomer of R9 (ssCre-dR9) and biotin
(ssCre-dR9-biotin) by EPL and explored whether these
elaborations in the resulting CPP enhance the effective-
ness of the intracellular delivery or allow cell imaging.
Results and discussion
The Cre-intein-His protein was expressed in E. coli and
purified in its native form by Ni2+-agarose column chroma-
tography. We generated a Cre-thioester by intein-mediated
cleavage using MESNA and then ligated the resultant
Cre-thioester with CGSGG-R9 or CGSGG-dR9 by native
chemical ligation. To minimize any potential adverse ef-
fect of MESNA on the activity of Cre, we first performed
the intein-mediated cleavage reaction with 50 mM
MESNA at 4°C for 24 h. Under this condition, more
than 95% of the Cre-intein-His proteins were cleaved into
Cre and the intein-His (lane 4 and lane 5 of Figure 2A).is was induced by the addition of IPTG (lane 3). Cre-intein-His was
as cleaved by MESNA and ligated with CGSGG-R9 peptide at 4°C for
y Ni-NTA chromatography (lane 6) and gel filtration (lane 7). Lane 1,
ue R-250. (B) The 12.5% SDS-PAGE gel was run for a longer running
3). Cre was prepared by the DTT-mediated cleavage of Cre-intein-His
lue R–250. The ratio of Cre-R9:Cre-thioester, which was estimated from
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intein-His protein into the ligation product of Cre-R9
through a two-step one-pot reaction (Scheme 2 of
Figure 1). EPL proceeds through the following three
reactions; the intein-mediated cleavage reaction by thiol
reagents, the transthioesterification reaction between the
thiol group of an N-terminal cysteine of the peptides and
the Cre-thioester, and the spontaneous intramolecular
S→N acyl shift that generates an amide bond at the
ligation junction. The first two reactions are reversible,
but the last reaction is irreversible. The irreversibility of
the last amide-forming reaction allows the two-step one-
pot reaction, in which the intein-mediated cleavage and
the native chemical ligation proceed in one pot, resulting
in a high yield of the final ligation product. We conducted
the two-step one-pot EPL reaction with 2 mg/ml Cre-
intein-His and a 10-fold excess of CGSGG-R9 in 50 mM
MESNA, 50 mM NaH2PO4, and 250 mM NaCl, pH 8.0
at 4°C for 24 h. The intein-His proteins, MESNA, and
CGSGG-R9 were then removed from the final ligation
product by Ni2+-agarose column chromatography and
subsequent gel filtration chromatography (Figure 2A).
Cre-R9 migrates slowly compared to Cre and forms the
distinct up-shifted band on SDS-PAGE (Figure 2B). Conju-
gation efficiency was calculated from integrated peak areas
of densitometry analysis of the Coomassie-stained SDS-
PAGE gels. Typically, 84% of Cre was conjugated into
Cre-R9, and the final yield of Cre-R9 was more than
2 mg from 20 mg of the Cre-intein-His protein. We
named the final Cre-R9 product produced by EPL as the
semisynthetic Cre-R9 (ssCre-R9).
We next determined whether Cre proteins retain their
activity after the conjugation of R9 peptides by expressed
protein ligation. Control Cre was generated from the Cre-Figure 3 Activity of Cre-R9 remains intact after EPL. Linearized pGEM-T
at one end. Cre-mediated recombination between two LoxP sites results in
Cre and the semisynthetic Cre-R9 (ssCre-R9) were incubated with the line
proteins by phenol extraction, DNA was analyzed by agarose gel electropintein-His protein by intein-mediated cleavage with DTT
instead of MESNA. Assays of the Cre enzyme activity
measured the release of a circular Kmr from the linearized
pGEM-T with floxed-Kmr by the site-specific recom-
bination of Cre (Figure 3). The maximum activity was
observed at 80 ng/reaction for both the control Cre and
ssCre-R9. This finding demonstrates that the conjuga-
tion of CGSGG-R9 to Cre by EPL does not impair the
enzymatic activity of Cre.
One major issue in developing a semisynthetic method
to produce cell-permeable Cre proteins is whether the
functionalities of cell-permeable Cre proteins are main-
tained during the semisynthetic process. Human TE671
(LoxP-LacZ) cells harbor a loxP-STOP-loxP LacZ reporter
gene, which allows us to assess the cellular uptake, subcel-
lular localization and enzymatic activity in the nucleus of
Cre proteins (Figure 4A). In order for the transduced Cre
proteins to elicit recombination, the exogenous Cre pro-
tein is required to enter the cell, translocate to the nu-
cleus, and remove the STOP sequence by recombination
at two loxP sites. It results in the expression of lacZ, and
the cells expressing β-galactosidase turns blue in X-gal
staining assay. The transfection of pBS185CMV-Cre plas-
mid DNA using Lipofectamine induced recombination in
40% of cells (Figure 4). It indicates that Cre proteins with-
out any additional NLS are able to enter the nucleus and
elicit recombination in human TE671 cells.
When treated with the control Cre (R9-CPP minus), few
lacZ-expressing cells were observed (Figure 4). In contrast,
treatment with ssCre-R9 showed a dose-dependent in-
crease in recombination. Treatment with 80 μg/ml ssCre-
R9 induced recombination in 94% of cells. The EC50app
value was measured to be 42.7 μg/ml (1.07 μM) (Table 1).
Because 84% of Cre was conjugated to Cre-R9 in the(LoxP Kmr LoxP) is 4,096 bp in length and contains a LoxP Kmr LoxP
a linear (3,000 bp) pGEM-T (LoxP) and a circular (1,096 bp) LoxP-Kmr.
arized pGEM-T (LoxP Kmr LoxP) at 37°C for 1 h. After isolated from
horesis. M, Lambda DNA digested with EcoRI and HindIII.
Figure 4 Protein transduction of the semisynthetic Cre-R9 and Cre-dR9. (A) Cre-mediated recombination of the floxed STOP cassette leads to
LacZ expression in human TE671 (LoxP-LacZ) cells. (B) The cells were exposed to varying doses of Cre, ssCre-R9, ssCre-dR9, and TAT-Cre in OPTI-MEM
for 5 h. The cells were further incubated with the serum-containing media for a total of 48 h, and then the percentage of LacZ-expressing cells
was determined by X-gal staining (n = 4; mean ± SD). The pCMV-Cre expression DNA plasmid was transfected using Lipofectamine.
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ssCre-R9 was estimated to be 35.9 μg/ml (0.9 μM).
TAT-Cre and Cre-R11 purified as recombinant fusion
proteins from E. coli are commercially available, and
the EC50 of TAT-Cre was measured to be 46.6 μg/ml
(1.14 μM) in a parallel experiment (Table 1). Transduction
activity of Cre-R11 appeared to be very low; the number
of lacZ-expressing cells obtained through the treatment
of TE671 cells with Cre-R11 was too low to calculate
the EC50 value. This result demonstrates that ssCre-R9
is more or at least equally effective for intracellular deliv-
ery than the recombinant TAT-Cre or Cre-R11 fusion pro-
tein. As reported for the recombinant TAT-Cre protein,
the delivery of ssCre-R9 into the cells was also rapid, and
treatment with 60 μg/ml ssCre-R9 for 1 h induced recom-




ssCre-R9 42.7 ± 3.8 μg/ml
(1.07 μM)
35.9 ± 3.2 μg/ml
(0.9 μM)
ssCre-dR9 37.2 ± 4.1 μg/ml
(0.93 μM)
31.2 ± 3.4 μg/ml
(0.78 μM)
TAT-Cre (A company) - 46.6 ± 6.0 μg/ml
(1.14 μM)
Cre-R11 (B company) - NAc
aFour independent experiments were performed (n = 4; mean ± SD). bEC50real
is defined as EC50real = EC50app x the conjugation efficiency.
cNA, not available.
The transduction activity of Cre-R11 was too low for EC50real to be measured.ssCre-R9 was non-toxic to the cells at concentrations up
to 160 μg/ml (Additional file 2: Figure S2).
It has been shown that the d-isomer R9 peptide labeled
with a fluorescent probe had a five-fold lower Km value
than the l-isomer R9 peptide for cellular uptake [7]. How-
ever, the cellular uptake mechanisms of CPPs vary de-
pending on the size and nature of the cargos [24], and
it has not been rigorously examined yet whether the d-
isomer polyarginine CPPs works better than the l-isomer
polyarginine CPPs for the delivery of large-size protein
cargos [20]. In this study, we conjugated CGSGG-dR9 to
Cre by EPL and produced ssCre-dR9 with a similar con-
jugation efficiency, purity, and overall yield as ssCre-R9.
To compare the abilities of ssCre-R9 and ssCre-dR9 to
enter cells, we treated human TE671 (loxP-LacZ) cells with
ssCre-R9 and ssCre-dR9 and scored the recombination
events based on the transduced Cre proteins (Figure 4).
At concentrations less than 20 μg/ml, ssCre-R9 and
ssCre-dR9 were equally non-effective. However, the dose-
dependent increase in recombination obtained with ssCre-
dR9 was steeper than that obtained with ssCre-R9, and
the EC50app values for ssCre-dR9 and ssCre-R9 were
37.2 μg/ml and 42.7 μg/ml, respectively (Table 1). We
consistently observed that the EC50 of ssCre-dR9 was
at least 10% lower than that of ssCre-R9, although the
difference in the EC50 values between ssCre-dR9 and
ssCre-R9 was not as marked as the difference in the Km
values between the d-isomer R9 peptide and the l-isomer
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lular uptake of the peptides at 3°C for 240 s by FACS after
trypsin treatment [7], and this method cannot differentiate
the peptides delivered to the cytosol from those incorpo-
rated into the plasma membrane or trapped in endosomes.
These differences in the assay methods and in the size and
nature of the cargos may explain the discrepancy in the
extents of the effects of the d-isomer on the efficiency of
cellular uptake. Nonetheless, these results clearly demon-
strate that the d-isomer polyarginine is more efficient than
the l-isomer polyarginine even for the delivery of large-size
protein cargos.
The guanidinium group of arginine-rich CPPs forms a
bidentate bond with the negative-charged lipid compo-
nents of a membrane and generates a negative Gaussian
membrane curvature, which induces the temporal and
dynamic topological transformation of the membrane
structure to the mesh phase [10,25]. CPPs have been pro-
posed to translocate into the inside surface of a membrane
via an adaptive translocation during this phase transition.
Therefore, the engineering of the membrane curvature
may be a strategy for the promotion of the cellular uptake
of CPPs. Indeed, it was found that epsin N-terminal
peptide 1–18 (EpN18), a peptide that induces a positive
curvature, accelerates the translocation of R8 peptides
into cells [26]. However, the effect of membrane curvature
on the cellular uptake of CPPs with large-size protein
cargos has not yet been examined. In this study, we
treated human TE671 (LoxP-LacZ) cells with ssCre-R9
and ssCre-dR9 in the presence of EpN18 and scored
the recombination events (Figure 5). EpN18 promotes
recombination in a dose-dependent manner when used
at a concentration near the EC50 of ssCre-R9 or ssCre-
dR9, 40 μg/ml. The acceleration effect of EpN18 started
to be observed at 10 μM, and recombination was observed
in 91% of cells exposed to 80 μM EpN18 and 40 μg/ml
ssCre-dR9. The acceleration effect of EpN18 was also ob-
served in the cells treated with a suboptimal concentration
of ssCre-R9 and ssCre-dR9, 20 μg/ml. In this case, how-
ever, the acceleration effect of EpN18 became obvious atFigure 5 Enhancement of the transduction of ssCre-R9 and ssCre-dR9 by
(A) or 40 μg/ml (B) Cre in the presence of varying amounts of EpN18 for 5 h. T
total of 48 h, and the expression of LacZ was then examined by X-gal staininghigher concentrations, such as 40 and 80 μM. Taken to-
gether, these results demonstrate that EpN18 is able to
promote the cellular uptake of polyarginine CPPs with
large-size protein cargos. Because EpN18 is not toxic to
cells [26], EpN18 may be useful as a booster for the pro-
tein transduction of ssCre-R9 or ssCre-dR9 to cell types
that are not amenable to protein transduction.
The visualization of the cells transduced with therapeutic
cell-permeable proteins will be highly advantageous for
post-treatment evaluation. As the first step to explore
this possibility, we synthesized dR9-biotin [NH2-Cys-
Gly-Ser-Gly-Gly-D (Arg)9-Gly-Gly-Lys (biotin)-amide] and
conjugated dR9-biotin to Cre by EPL. ssCre-dR9-biotin
was produced with a similar purity and overall yield as
ssCre-dR9. We found little difference in the transduction
efficiency between ssCre-dR9 and ssCre-dR9-biotin. To
visualize the ssCre-dR9-biotin delivered into cells, the
cells were treated with ssCre-dR9-biotin for 5 h, washed
with PBS, fixed with paraformaldehyde, and then stained
with avidin-FITC. Images taken using a confocal laser
scanning microscope showed both cytoplasmic and nu-
clear staining with a distinct pattern (Figure 6). A previous
study raised the possibility that cell fixation leads to the
artifactual redistribution of CPP [27]. Therefore, it is
unlikely that ssCre-dR9-biotin has the same subcellular
localization in living cells demonstrated by avidin-FITC
staining in this study. Nonetheless, these results clearly
demonstrated the applicability of EPL for the preparation
of cell-permeable proteins with biotin for cell imaging. For
in vivo imaging of whole animals or cells, it will be more
advantageous to use CPPs with fluorophores instead of
biotin. It will be interesting to devise a near-infrared (NIR)
fluorophore that can be located near CPP without ham-
pering the delivery and activity of proteins in cells.
Conclusions
In this study, we devised an EPL-based technique to conju-
gate synthetic polyarginine CPPs to Cre protein expressed
in E. coli without impairing the enzymatic activity of Cre.
The ligation product, ssCre-R9, exhibited comparable orEpN18. Human TE671 (LoxP-LacZ) cells were exposed to either 20 μg/m
he cells were further incubated with the serum-containing media for a
(t-test; * P < 0.05, ** P < 0.01, *** P < 0.001). Error bars, mean ± SD (n = 3).
Figure 6 Cellular imaging of the internalized ssCre-dR9-biotin.
Human TE671 cells were treated with 80 μg/ml ssCre-dR9-biotin for
5 h (ssCre-dR9-biotin) or left untreated (Control). The cells were fixed
and then sequentially incubated with avidin-FITC, anti-avidin-biotin
antibody, and avidin-FITC. The fluorescence images were taken under a
confocal laser scanning microscope.
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combinant TAT-Cre and Cre-R11 fusion proteins directly
expressed in E. coli. Because all of the steps of EPL are de-
signed to proceed in the presence of high salt concentra-
tions, this approach avoids the technical hurdle caused by
the decrease in the solubility of polyarginine fusion pro-
teins when expressed in E. coli. In addition, this EPL-based
technique allowed us to prepare ssCre-dR9 and ssCre-dR9-
biotin containing poly-D-arginine and biotin as part of the
CPPs. ssCre-dR9 resulted in improved protein transduction
compared with Cre-R9, and ssCre-dR9-biotin allowed the
visualization of the cells transduced with ssCre-dR9-biotin.
The findings demonstrated the feasibility of this EPL-based
technique for the preparation of cell-permeable pro-
teins with higher transduction efficiency and more elab-
orate properties for use in more sophisticated applications,
such as cell imaging. EPL should find broad use for the
introduction of cell permeability to therapeutic proteins,




CGSGG-dR9 [NH2-Cys-Gly-Ser-Gly-Gly-D (Arg) 9-amide],
EpN18 [26], and dR9-biotin [NH2-Cys-Gly-Ser-Gly-Gly-D
(Arg) 9-Gly-Gly-Lys (biotin)-amide] were synthesized
and provided by Peptron Inc. The peptides were purified
by high-performance liquid chromatography to a purity
>90% and confirmed by mass analysis.
Preparation of the Cre-intein fusion protein
Cre recombinase DNA was obtained from pBS185CMV-
Cre (Addgene plasmid 11916) through two amplification
steps, first using the forward primer 5′-GAG CAT ATG
TCC AAT TTA CTG ACC GTA CAC-3′ and the re-
verse primer 5′-GTA CTC GAG ATC GCC ATC TTCCAG GAC-3′ and then using the forward primer 5′-GAG
CAT ATG TCC AAT TTA CTG ACC GTA CAC-3′ and
the reverse primer 5′-GCG TGC TCT TCC GCA GTA
CTC GAG ATC GCC ATC-3′ [28]. The amplified DNA
was inserted into the Nde I and Sap I sites on the
pTWIN_His vector (Jena Bioscience) to construct an
expression plasmid for a recombinant fusion protein
of Cre and mini-intein (derived from Mycobacterium
Xenopi gyrase A, Mxe GyrA) combined with a 6× His-
tag. Leu-Glu-Tyr was inserted between Cre and intein
to improve the intein-mediated cleavage. The pTWIN_Cre
plasmid encoding the Cre-intein-His fusion protein was
transformed into E. coli BL21 (DE3) cells. Then, 50-ml LB
medium overnight culture were inoculated into 1 L of LB
medium with ampicillin (50 μg/ml) and grown at 37°C.
When OD600nm reached to 0.6, yeast extract was added to
1% and then the expression of Cre-intein-His was induced
by 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) at
37°C for 3 h. The E. coli cells were harvested by centrifu-
gation and resuspended with 5× packed cell volume of
lysis buffer (20 mM NaH2PO4, 300 mM NaCl, and 10 mM
imidazole, pH 8.0), treated with 1 mg/ml lysozyme on ice
for 30 min, and then lysed via sonication. The soluble
supernatant was collected by centrifugation at 10,000 × g
and mixed with 10 ml of the 50% slurry of Ni-NTA resin
(Qiagen) at 4°C for 1 h. The resin slurry was packed into a
column and washed with five column volumes of washing
buffer (50 mM NaH2PO4, 300 mM NaCl, and 50 mM
imidazole, pH 8.0). The Cre-intein-His protein was eluted
from the column with elution buffer (50 mM NaH2PO4,
300 mM NaCl, and 250 mM imidazole, pH 8.0). The
fractions containing the Cre-intein-His protein were com-
bined and dialyzed against cleavage buffer (50 mM NaH2PO4
and 250 mM NaCl, pH 8.0) at 4°C overnight.Intein-mediated cleavage and ligation of Cre-thioester
with polyarginine polypeptides
The intein-mediated cleavage to generate the Cre-thioester
and the ligation of the Cre-thioester with polyarginine
polypeptides were performed at the same time. The Cre-
intein-His protein in cleavage buffer (50 mM NaH2PO4
and 250 mM NaCl, pH 8.0) was incubated with 50 mM 2-
mercaptoethanesulfonate (MESNA) and a 10-fold molar
excess of CGSGG-R9 or CGSGG-dR9 at 4°C for 24 h.
To separate Cre-R9 from the Cre-intein-His or intein-His
proteins, the reaction mixture was loaded onto a Ni-
NTA column equilibrated with lysis buffer, and the
flow-through fraction was collected. Cre-R9 was treated
with dithiothreitol (DTT) to a final concentration of
10 mM, incubated on ice for 30 min, and then concen-
trated using a Pierce concentrator 9K (Thermo) at 4°C.
Any leftover MESNA and peptides in Cre-R9 were removed
by a spin column packed with Sephadex G25 Fine resin
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NaH2PO4, 300 mM NaCl, and 1 mM DTT, pH 8.0).Cell culture
Human TE671 (LoxP-LacZ) cells were purchased from
Allele Biotech. The cells were cultured at 37°C in a 5%
humidified CO2 incubator in Dulbecco’s Modified Eagle’s
medium (DMEM) with 10% fetal bovine serum, 100 U/ml
penicillin G, and 100 μg/ml streptomycin.Protein transduction assay
TAT-Cre and Cre-R11 were purchased commercially. To
measure the rate of Cre-R9 internalization and subsequent
recombination, human TE671 (LoxP-LacZ) cells were plated
onto 24-well plate at 7 × 103 cells/well. After one day, the
cells were washed once with OPTI-MEM (Gibco) and incu-
bated with 300 μl of OPTI-MEM containing Cre proteins
for 5 h. The medium was changed to DMEM containing
10% FBS, and the cells were then further incubated for 43 h.
The recombination at LoxP sites by Cre proteins in the cells
was measured by a LacZ enzyme assay. The cells were
washed twice with cold PBS and fixed with 300 μl of a
fixation solution (1% formaldehyde and 0.2% glutaralde-
hyde in PBS) at room temperature for 5 min. The cells
were washed three times with PBS and incubated with
300 μl of an X-gal staining solution (4 mM K-ferrocyanide,
4 mM K-ferricyanide, 2 mM MgCl2, and 0.4 mg/ml X-gal
in PBS) at 37°C overnight.In vitro assay of Cre activity
Cre protein was added to 50 μl of reaction buffer
(50 mM Tris–HCl, 33 mM NaCl, and 10 mM MgCl2,
pH 7.5) containing 0.3 μg of linearized pGEM-T (floxed-
Kmr) and incubated at 37°C for 1 h. Cre was then heat-
inactivated by incubation at 70°C for 10 min. After
isolation from proteins by phenol extraction and
EtOH precipitation, DNA was analyzed by agarose gel
electrophoresis.Fluorescence imaging
Human TE671 cells grown on gelatin-coated glass cover-
slips were incubated with 80 μg/ml ssCre-dR9-biotin in
OPTI-MEM for 5 h. The cells were washed three times
with PBS and fixed in 3.7% (v/v) paraformaldehyde for
15 min at room temperature. The cells were sequentially
incubated with avidin-FITC, anti-avidin-biotin antibody,
and avidin-FITC each for 30 min at room temperature.
After mounting with 90% glycerol and 0.1% o-phenyl-
enediamine in PBS, cellular images were obtained using
a confocal laser scanning microscope.Additional files
Additional file 1: Figure S1. One hour of incubation with exogenous
ssCre-R9 is sufficient for Cre-mediated recombination in human TE671
(LoxP-LacZ) cells. Cells were exposed to 60 μg/ml of ssCre-R9 in OPTI-MEM for
the indicated time. Cells were further incubated with the serum-containing
media for the total 48 h, and then the expression of LacZ was examined
by X-gal staining (n = 4; mean ± SD).
Additional file 2: Figure S2. ssCre-R9 does not affect cell viability. Human
TE671 (LoxP-LacZ) cells were incubated with ssCre-R9 in OPTI-MEM for 5 h
and further incubated with the serum-containing media for a total of 48 h.
Cell viability was measured by MTT assay (n = 3; mean ± SD).
Abbreviations
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